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MANUSCRIPT BODY 
 
This article reports on the sixth scientific workshop of the European Crohn’s and Colitis 
Organisation (ECCO) on the pathogenesis of extraintestinal manifestations (EIM) in 
inflammatory bowel disease (IBD). This paper has been drafted by 15 ECCO members and 6 
external experts (rheumatology, dermatology, ophthalmology and immunology) from 10 
European countries and the USA. Within the workshop contributors formed subgroups to 
address specific areas. Following a comprehensive literature search, the supporting text was 
finalised under the leadership of the heads of the working groups before being integrated by 
the group consensus leaders.  
 
INTRODUCTION 
Up to 50% of IBD patients experience at least one extraintestinal manifestation (EIM).1 The 
pathogenic mechanisms of EIM are not clearly defined. Unravelling these pathways has the 
potential to enhance our understanding of the pathogenesis not only of EIM but also of IBD 
overall. Defining pathogenic pathways in EIM is challenging due to the lack of consistent 
criteria for diagnosis and difficulty in distinguishing drug-induced extraintestinal pathologies 
from EIM. Optimising treatment may also be problematic. For many EIMs commonly 
accepted definitions and high quality evidence supporting different treatment strategies are 
lacking.2 Therefore, there is a great need for both basic science studies and clinical trials to 
understand pathogenesis and determine optimal treatment of EIM. The first ECCO European 
Evidence-based consensus on EIM in IBD provided an authoritative guideline for the clinical 
management of EIM.2 The current article seeks to complement and extend the clinical 
guideline by identifying frontiers and open questions for clinical research.  
 
DEFINITION 
In order to standardize systematic inclusion of patients in scientific and clinical studies and 
align outcome measures to ensure clarity across the scientific literature, widely agreed upon 
definitions of the pathology being studied are critical. In order to provide a frame of 
  
reference for scientific discourse the expert panel suggests the following mechanistic 
definition of what constitutes an EIM: 
 
“An inflammatory pathology in a patient with IBD that is located outside the gut whose 
pathogenesis is either dependent on extension/translocation of immune responses from the 
intestine, or is an independent inflammatory event perpetuated by IBD or that shares a 
common environmental or genetic predisposition with IBD.” 
 
A wide range of extraintestinal pathologies are associated with IBD, however not all of these 
would be considered to be true EIM according to the definition above. The panel proposes 
that current data supports pathologies listed in the first column of Table 1 as true EIM, with 
other pathologies classified as associated auto-immune conditions or complications of IBD 
and its treatment. The distinction between these categories can be imprecise and overlap 
likely exists; it is probable that with future new data some pathologies will be re-classified. 
For the purpose of this review the panel focussed on true EIM as described by the definition 
above. 
 
BASIC MECHANISMS OF EIM 
Immunological mechanisms  
The potentially diverse immune mechanisms that underlie EIM are poorly defined. We 
discuss two distinct theories that mechanistically link inflammation in the intestine and at 
other sites. First, EIM arise from an extension of antigen specific immune responses from the 
intestine to non-intestinal sites. Second, EIM are independent inflammatory events initiated 
or perpetuated by presence of IBD or by shared genetic or environmental risk factors in the 
host. These mechanisms are not mutually exclusive and may contribute to varying degrees in 
different EIM (Figure 1). 
Extension of immune responses from the intestine 
Ectopic expression of gut-specific chemokines and adhesion molecules: 
Abnormal patterns of lymphocyte homing in IBD may contribute to EIM3. Expression of the 
vascular addressin MAdCAM-1 is normally restricted to intestinal tissue and, in the context 
  
of specific chemokine signals, enables gut tropic T cells that express α4β7 integrin to traffic 
selectively to the intestinal mucosa. Additional tropism for the small intestine comes from 
the chemokine CCL25 attracting lymphocytes expressing its receptor CCR9. Ectopic 
expression of both chemokines and adhesion molecules can occur in IBD4, and may facilitate 
trafficking of inflammatory T cells to extraintestinal sites. The best supporting evidence 
comes from IBD associated primary sclerosing cholangitis (PSC). Ectopic expression of both 
MAdCAM-1 and CCL25 has been demonstrated in the vascular endothelium of the portal 
tract.5, 6 One fifth of the infiltrating T cells co-express CCR9 and α4β7, whereas the frequency 
of these cells is low in other forms of liver inflammation, indicating an important role for 
these molecules in recruitment of inflammatory lymphocytes in PSC.6 While attractive to 
propose ectopic expression of gut-associated addressins at extraintestinal sites as a logical 
mechanism for EIM, evidence that this occurs in organs other than liver is lacking. However, 
co-expression of α4β7 with cutaneous leukocyte antigen (CLA), (implicated in homing to the 
skin), by some blood T cells from IBD patients7, may indicate that gut generated effector cells 
can acquire both gut and skin tropism. 
T cell trafficking driven by non-specific adhesion molecules: 
Upregulation of inflammation-associated adhesion molecules and chemokines that lack 
tissue restriction may also enable capture of effector cells facilitating their recruitment into 
non-intestinal sites. Gut leukocytes from IBD patients are able to bind to the synovial 
membrane, using a repertoire of adhesion molecules8, but mainly using endothelial vascular 
adhesion protein 1 (VAP-1)9. VAP-1 also plays a role in transmigration of lymphocytes across 
hepatic endothelium and its expression is upregulated by inflammation.10, 11  T cells from 
intestinal mucosa of IBD patients express chemokine receptors, such as CXCR3 and CCR5,12, 
13 that may contribute to their ability to enter other tissues. Low-grade inflammation, injury 
or mechanical stress at extraintestinal sites (as implicated in the pathogenesis of 
spondyloarthritis (SpA)14 and pyoderma gangrenosum, where this phenomenon is termed 
pathergy) may nucleate the recruitment of gut-generated effector cells and further enhance 
the inflammatory process. 
Microbial antigen translocation and/or cross-reactivity:  
Models of EIM that invoke trafficking of gut effector T cells raise the question as to whether 
this process is dependent on antigen specific reactivation at non-intestinal sites and if so, 
  
what the antigen may be. Antigens derived from the gut microbiota are believed to be key 
targets for intestinal effector T cells in IBD and transport of these antigens to the liver via the 
portal circulation may activate such cells localised here via α4β7-MAdCAM-1 interactions 
and other pathways. The presence of distinct gut microbiota in IBD patients with PSC15-17 
may suggest specific bacterial antigens. At other sites, cells may be reactivated by cross-
reactive components of the resident microbiota or host antigens. Molecular mimicry, in the 
form of peptide sequences common between enteric bacteria and host MHC molecules has 
been reported18, 19 although the pathologic significance of this is unclear. In mice, retina-
specific T cells that cause uveitis require activation in the gut by a microbiota dependent 
signal, most likely a cross reactive bacterial antigen,20 providing evidence for a direct link 
between gut microbiota, recognition of self-antigens and inflammation at a non-intestinal 
site. Indeed, leukocyte trafficking between the gut and the eye has been demonstrated in 
experimental models of autoimmune uveitis.21 However, the antigen specificity of T cells 
responsible for EIM in humans has never been defined.  
Circulating antibodies: 
Circulating antibodies could extend intestinal immune responses to additional sites and 
immune complex mediated inflammation has been proposed to contribute to certain EIM22. 
Autoantibodies reactive to colonic proteins have been identified in patients with IBD23, 24 
and, using monoclonal antibodies, epitopes shared between human colon and tissues such 
as eyes, joints, skin and biliary epithelium have been identified.25-27 However, clear evidence 
of a causative role for antibodies or immune complexes in the pathogenesis of EIM in IBD 
patients is lacking. 
 
EIM as independent inflammatory events 
A shift in inflammatory tone favours the development of EIM:  
An alternative explanation for EIM would see them as independent inflammatory events 
sharing common genetic28 or environmental29 risk factors with IBD. The presence of 
intestinal inflammation and/or microbial dysbiosis in individuals with IBD might further 
increase the risk of developing extraintestinal inflammation through modulation of 
inflammatory ‘tone’, impacting on immune functions at other sites. Key inflammatory 
mediators, including IL-6, TNF, IFNγ and VEGF30 are raised in serum of IBD patients, as is 
  
bacterial LPS31 which may promote cytokine production via activation of immune cells at 
non-intestinal sites. Systemic effects, including increases in epithelial permeability32 and up-
regulation of neutrophil extravasation ligands on vascular endothelium, may lower the 
threshold for immune activation at extraintestinal sites. IBD associated cytokines, such as IL-
23, which is produced at high levels in CD and UC, can activate immune cells resident within 
the synovial membrane and drive spondyloarthropathy.33 
Systemic changes in innate immune function: 
Exposure of neutrophils to inflammatory cytokines or other signals can enhance their 
response upon subsequent activation, a phenomenon termed neutrophil priming.34 
Circulating neutrophils show morphological evidence of activation in IBD35 and are primed to 
produce increased levels of TNFα and IL-1β.36 In contrast, recruitment of neutrophils to the 
skin and clearance of subcutaneous bacteria is reduced in patients with CD37. Likewise, 
changes in circulating monocytes38 and macrophages derived from blood monocytes37 have 
been reported in IBD, with reduced inflammatory cytokine production in response to 
bacterial stimulation.  
Altered haematopoiesis: 
Changes in circulating immune cells observed in IBD are likely to reflect altered 
haematopoiesis in the bone marrow. In mouse models, haematopoiesis is influenced by both 
microbial products39-43 and the presence of intestinal inflammation.44, 45 In IBD, systemic 
inflammatory cytokines, increased permeability of the intestine to microbial products or 
changes in the composition and metabolic products of the microbiota, could all influence the 
generation of innate immune cells.46, 47  
 
Dysbiosis and gut microbiota 
The long-established link between gut infections with enteric pathogens such as Salmonella, 
Campylobacter, Yersinia and Shigella and reactive arthritis is a clear indication that potential 
pathogenic pathways between microbiota in the gut and extraintestinal inflammation exist. 
Specific EIM are associated with gut dysbiosis: Patients with SpA have decreased faecal gut 
microbial diversity and increased abundance of Ruminococcus gnavus and genus Dialister, 
which positively correlated with disease activity.48,49 Patients with psoriatic arthritis also 
  
exhibit decreased faecal microbial diversity.50 In addition, faecal Saccharomyces cerevisiae 
abundance is decreased in psoriasis compared to healthy controls.51 
PSC has also been associated with decreased faecal microbial diversity.15, 52 One study has 
suggested that IBD patients have similar dysbiosis to IBD-PSC patients.17 However, a 
conflicting report53 makes it difficult to judge whether the risk for developing PSC is driven 
by specific microbial factors.17 There is a paucity of studies determining gut dysbiosis in 
individuals with inflammatory eye disease, although one study demonstrated differences in 
gut microbiota between healthy individuals and those with age-related macular 
degeneration54 and preliminary data suggested the existence of an intraocular microbiota.55 
There is a range of potential mechanisms by which gut microbiota drive the pathogenesis of 
EIM (Box 1).  
 
1. Molecular mimicry: similarity between gut microbiota and non-microbial epitopes 
present at the extraintestinal site 
2. Microbial communities in the extraintestinal site: similarities with pro-inflammatory 
gut microbiota could drive extraintestinal inflammation 
3. Microbial translocation: Microbiota or their components are translocated from the 
gut to the extraintestinal site, (e.g. to the liver via the portal circulation) 
4. Soluble microbial derived factors: e.g. LPS may be released into the circulation and 
promote inflammation at extraintestinal sites. 
5. Disruption of gut barrier: Specific microbiota such as mucin degraders may disrupt 
the gut mucosal barrier, facilitating leakage of cellular or non-cellular factors into the 
circulation 
6. Microbiota-derived metabolites: e.g. metabolism of bile acids and generation of 
short-chain fatty acids which could both alter immune signalling 
7. Acquisition of deleterious microbiota in early life resulting in altered immune 
development, which in turn generates a persistent pro-inflammatory immune “tone” 
The first four of these hypothesized mechanisms have been included in the discussion in the 
preceding section. However, gut microbiota may promote inflammation at extraintestinal 
sites through metabolic activities. Ruminococcus which is altered in patients with arthritis 
could initiate breach of the intestinal barrier through mucin degradation.56 In rats gut 
  
microbiota-dependent alterations in bile acid deconjugation are associated with altered bile 
acid profiles in extraintestinal sites including kidney, heart, plasma and liver, demonstrating 
that gut microbial metabolic functions have the potential to influence immune signalling at 
distant sites.57 Short-chain fatty acids (SCFA) produced by many gut bacteria may have 
metabolic or immunomodulatory effects. In experimental autoimmune uveitis oral 
administration of SCFA attenuated uveitis severity and was associated with suppression of 
effector T cell induction.21 Furthermore, SCFA have a potential role in modulating T cell 
trafficking to extraintestinal sites. Finally it has been hypothesised that IBD linked dysbiosis 
may exert its pathogenic effect during immune development.58 This is supported by animal 
models with bacterial colonisation of mice at age 3 weeks resulting in a persistent 
inflammatory tone, whereas colonisation at age 1 week did not.59 Thus disruption of 
acquisition of gut microbiota early in life may generate persistent aberrant immune 
responses manifested in the gut or extraintestinally, or both. Indeed, factors that may 
influence the process of gut microbiota acquisition in early life such as breast feeding have 
been shown to be protective against the occurrence of ankylosing spondylitis (AS).60 
Open questions: 
1. Are the gut microbiota pathogenic in EIMs (via any of the mechanisms mentioned in 
the text) or are EIMs independent of gut microbiota? 
2. If microbiota play a role, what is the mechanism? 
3. If EIMs are driven by microbiota are these the same or different from those involved 
in IBD pathogenesis? 
4. Are microbial communities in other parts of the body involved in IBD pathogenesis? 
Genetic basis of extraintestinal manifestations 
Familial and epidemiological evidence: 
There is an extensive overlap in genetic risk loci for both IBD and EIM, particularly AS.61 
Association studies revealed a concordance in EIM present in 70% of parent-child pairs and 
in 84% of sibling pairs highlighting the role of genotype,62 (or early life environmental 
factors). In addition, the appearance of one EIM increases the probability of developing 
other EIM.1, 63 Further supporting the genetic underpinning of EIM, the CD risk gene NOD2, 
encoding a pattern recognition receptor, has also been associated with sacroiliitis,64 and 
  
uveitis.65 Several HLA genes and HLA independent loci have been associated with the 
presence of EIM and a detailed description can be found in the Supplementary information. 
The genetic contribution to the pathogenesis of EIM and IBD comprises a combination of 
overlapping and independent loci, a situation which is consonant with the occurrence of EIM 
in individuals both with and without evidence of gut inflammation. However, whether the 
involved loci all contribute to pathology in an EIM-specific fashion, or whether there are 
genes that liberate inflammatory responses from restriction to specific body compartments 
and thus give rise to EIM in general, is not known. 
 
Open questions: 
1. Are the genes that predispose to specific EIM in IBD patients the same as the genes 
that predispose towards the EIM pathology in non-IBD patients?  
2. Are there genes common to all EIM patients and distinct from non EIM IBD (immune 
mobility/ promiscuity factors)? 
3. Do IBD patients with no EIM have protective factors i.e. they have the same genetic 
risk as EIM patients but have additional (genetic or environmental) protective 
factors? 
Animal models of EIM 
Animal models where inflammation is manifested at more than one anatomical site or bodily 
system (multifocal inflammation) provide experimental platforms to dissect pathogenic 
pathways of EIM and serve as tools to test potential therapies. However, only few models 
manifest multifocal inflammation, with colitis-arthritis models being the dominant 
phenotype available. 
TNF∆ARE mice carry a genetic deletion of TNF AU-rich elements (ARE), leading to 
overexpression of TNF.66 The resulting phenotype is CD-like transmural and granulomatous 
chronic ileitis along with spondyloarthropathy-like sacroiliitis, Achilles tendon enthesitis and 
peripheral arthritis. Paradoxically (given the importance of innate immune responses in 
human IBD), in this model ileitis appeared to be dependent on the presence of mature T 
and/or B cells, as mice with TNF∆ARE in combination with a RAG-/- background developed 
only arthritis.66 Furthermore, mice with intestinal epithelial cell-specific TNF ARE deletion 
develop ileitis but not EIM,67 indicating that intestinal inflammation per se is not sufficient 
  
for induction of arthritis, which is therefore presumably dependent on local TNF production 
in the joint. Ileitis is abrogated in germ-free TNF∆ARE 68 and TNF∆ARE/β7-/- mice,69 but the 
effects of such manipulations on joint inflammation have not been reported yet. Taken 
together, in TNF∆ARE mice, gut and joint inflammation likely represent independent 
phenomena mediated by a common pro-inflammatory factor.   
HLA-B27 transgenic rats develop spondylarthritis and colitis, but also gastritis, psoriasis and 
epididymitis.70 In the intestinal mucosa there is increased production of pro-inflammatory 
cytokines (IFN-γ, IL-2, IL-1α, IL-1β, TNFα, and MIP2) and in addition plasma concentrations of 
TNFα and IL-6 are raised.  IL-23 and IL-17A may play important roles, in association with HLA-
B27 misfolding in the ER and activation of the unfolded protein response, leading to 
downstream inflammation.71, 72 Interestingly, in this model both colitis and arthritis (but not 
dermatitis and epididymitis) are dependent upon the presence of microbiota.73 The HLA-B27 
model is consistent with a common genetic origin of multi-organ inflammation, but also 
emphasises the fact that some but not all EIM are dependent on microbiota. However, when 
interpreting data from germ-free models it is important to consider that conventionally 
reared mice are not only colonised with microbiota in the gut but also other organs such as 
skin, joints and eye which may also play a role in pathogenesis. More detailed experiments 
may be required to determine the contribution of extraintestinal microbiota communities in 
animal models of inflammation. 
SKG mice that receive intraperitoneal injections of 1,3-β-glucan develop ileitis in association 
with enthesitis, arthritis, dactylitis, fasciitis, vertebral inflammation, and uveitis.74 Treatment 
with anti-IL-23 mAbs or genetic deletion of the downstream cytokine IL-17A abrogate both 
ileitis and arthritis.75 Time course expression studies identified intestinal mucosa as the 
source of elevated IL-23 production.75 Nevertheless, immunological pathways of joint and 
gut inflammation in this model are not identical, as IL-22 neutralization reduced the severity 
of enthesitis but exacerbated ileitis in 1,3-β-glucan-treated SKG mice. 
Animal models: Open questions 
1. Could further animal models with intestinal inflammation and extraintestinal 
involvement (including sites other than joints) be developed? 
2. Which common pathways between mucosal and extraintestinal inflammation are 
implicated in animal models where both occur? 
  
3. What is the role of microbiota (including faecal transplant) in the development of 
inflammation in animal models? 
4. Can animal models be used to elucidate the temporal relationship between intestinal 
disease and development of EIM? 
5. How should animal models be used to investigate novel mechanisms and therapies 
such as neuroimmunomodulation? 
 
Implications of the therapeutic effect of biologics and other treatments for EIM  
Emerging data for the efficacy of biologics for the treatment of EIM may serve to expose 
underlying pathogenic mechanisms. Most evidence is available for anti-TNFα with good 
response rates for cutaneous manifestations, arthritis and ocular EIM. This has implicated 
TNFα-dependent mechanisms in EIM pathophysiology.69-71, 76 However, anti-TNFα drugs are 
increasingly recognised to cause drug-induced skin lesions, contributing to the burden of skin 
disease in IBD.77, 78 The pathogenesis of these lesions remains unclear; blocking TNFα may 
result in an imbalance of cytokines (for example, increased IFNα release, which can cause 
psoriasis)79-81 and TNFα inhibition may lead to a reduced accumulation of Th1 and Th17 cells 
at the site of inflammation, but trigger a compensatory expansion at other locations.82 
Female gender and family history of inflammatory skin disorders were identified as risk 
factors which may also indicate a possible genetic predisposition for anti-TNFα induced skin 
lesions.83  
The gut selective mechanism of the integrin α4β7 antibody vedolizumab should restrict its 
activity to the gut, since its counterpart MAdCAM1 is not expressed in the human skin.84 The 
contribution of vedolizumab trials to understanding of EIM pathogenesis is complicated, 
since the evidence of its effect on EIM appears to be conflicting: One case series did not 
show any positive effect,85 while a recent analysis from France suggested positive effects on 
EIM in most cases, but also revealed new onset of arthritis and paradoxical skin lesions.86 
The pathogenic mechanisms behind these observations remain elusive.85 It may be 
speculated that a compensatory expansion of T cells at locations other than the gut could 
explain this phenomenon (similar to anti-TNFα induced lesions). On the other hand, a 
beneficial effect of vedolizumab on disease activity of EIM could occur if lymphocytes 
require the α4β7- MAdCAM1 interaction to gain access to the gut where they are activated, 
  
followed by non-α4β7-dependent entry to extraintestinal sites. There is also evidence in 
animal models that some regulatory T cells require α4β7dependent entry into the gut to be 
educated before expressing their function elsewhere; vedolizumab could theoretically 
interfere with this.87, 88 An alternative hypothesis is that α4β7 is directly involved in homing 
to extraintestinal sites as outlined above. It remains likely that vedolizumab has the capacity 
to illuminate pathogenic pathways in EIM. 
Data on other biological agents are limited. So far, no trial has been published evaluating the 
anti-IL12/23 antibody ustekinumab in the management of EIM. Case series suggest it has 
efficacy in the treatment of anti-TNFα induced skin lesions,89, 90 however, development of 
pustular psoriasis has been described.91 Whether ustekinumab is effective in the treatment 
of non-drug induced EIM has yet to be determined. In contrast to anti-IL12/23 and despite 
the pathogenic role of Th17 cells in the development of colitis, trials with anti-IL-17A have 
failed in IBD with even higher adverse rates than placebo.92 Moreover, in contrast to its 
efficacy in other inflammatory disorders, anti-IL-17A can even exacerbate IBD activity,93 
which highlights a distinct involvement of the IL-17A pathway in these entities. No data on 
JAK inhibitors is available so far, but upregulation of STAT3 in erythema nodosum and 
pyoderma gangrenosum84 makes a response to JAK inhibitors reasonable to predict and 
sheds light on the possible involvement of the JAK-STAT pathway in cutaneous EIM.  
Taken together, it is important that clinical trials and observational studies of biologic agents 
are designed to optimise the capture of data on effects on inflammation in other systems 
than the disease defined in the primary outcome. 
 
Open questions: 
1. How does vedolizumab affect EIM? Does it have the same effect on all EIM? 
2. What is the implication of the overexpression of STAT for the prospect of using JAK-
inhibitors for treating PG and EN? 
3. How will EIM respond to IL12/23 treatment? 
 
CLINICAL RESEARCH 
Despite the presence of a wide range of EIM associated with IBD, standardized criteria for 
diagnosis, documentation or monitoring are lacking. Thus far only one randomized 
  
controlled trial including IBD patients with EIM has been conducted.94 Here we discuss the 
currently available paradigms and tools for clinical research in three of them: skin, joint and 
eye EIMs.  
Diagnosis and monitoring of EIM 
Because the diagnostic and monitoring tools for EIM have been developed within the organ-
based specialities, this section is presented according to an organ-based structure. 
Clinical criteria, indexes and scales 
Joint manifestations: 
IBD-associated joint symptoms may be subdivided into inflammatory and non-inflammatory 
joint pain, (arthritis and arthralgia respectively).95, 96 Inflammatory arthropathies in IBD are 
the most common EIM and belong to the spondyloarthritis (SpA) group with a prevalence of 
20-50% for axial inflammation,97-99 and 5-20% for peripheral arthritis.100, 101 The Assessment 
of SpondyloArthritis International Society (ASAS) developed classification criteria for both 
inflammatory axial and peripheral joint disease. These criteria are the current standard for 
clinical trials research  and have good performance as tested against the rheumatologist's 
diagnosis (Supplementary Figures 1 and 2).102-104 However, limited data evaluate ASAS 
criteria specifically in IBD patients. In IBD patients with inflammatory back pain ASAS criteria 
have an equivalent sensitivity but lower specificity compared to non-IBD patients.105 This 
lower specificity may be due to the inclusion of IBD as one of the ASAS criteria of axial 
spondyloarthritis. Alternative classification tools such as the Amor classification106 and the 
European Spondyloarthropathy Study Group (ESSG) criteria107 also include IBD as a criterion, 
whereas the older Modified New York classification do not.108 Nevertheless, in order to 
ensure applicability of research data to clinical practice it is advantageous that the definition 
of patient groups in clinical trials and research is consistent with that used rheumatology (i.e. 
ASAS criteria). Therefore, validation of these currently used tools in IBD patients should be 
carried out. 
Monitoring tools for determining response to treatment and disease outcomes have also 
been developed by ASAS. The current gold standard tool for axial spondyloarthritis is the 
Ankylosing Spondylitis Disease Activity Score (ASDAS),109 providing both a measurement of 
disease activity that may be followed over time as well as cut-offs to allow grouping of 
patients into different disease activity states (Supplementary Figure 3). ASDAS includes back 
  
pain as one of the criteria. Hence, it is not well-adapted for use in the 5-20% of IBD patients 
with peripheral arthritis. In response to the lack of validated outcome measures in 
peripheral spondyloarthritis the authors of one randomized controlled trial of adalimumab in 
patients with non-psoriatic peripheral spondyloarthritis developed a new outcome measure, 
the Peripheral SpA Response Criteria (PSpARC40) measured after 12 weeks of treatment.110 
However, this outcome measure has not been widely applied and there is a need to validate 
the use of these tools in patients with multifocal inflammation. 
Eye manifestations:  
The most common eye EIMs are episcleritis and anterior uveitis. Scleritis and posterior or 
intermediate uveitis are rarer, but pose a greater potential risk to sight. Supplementary 
Figure 4 summarizes some of the more common types of inflammatory eye disease as well 
as some of the ocular complications of IBD and its treatment. Episcleritis is usually treated 
topically with corticosteroids or non-steroidals. Uveitis may pose a greater diagnostic and 
therapeutic challenge. The SUN (Standardisation of Uveitis Nomenclature) classification is 
internationally acknowledged and as such research and clinical trials in uveitis in IBD patients 
should follow this system (Supplementary tables 2-7).111, 112 SUN classification may be used 
both for diagnosis and classification of uveitis at presentation as well as for monitoring 
disease progression. However, it is relevant to consider that the SUN classification may have 
limitations especially for judging significance of the outcome of clinical interventions. The 
FDA defines a significant clinical response as 2-step change in parameters of the SUN 
classification, but many successful therapies do not meet the required 2 step improvement 
(especially in vitreous haze). Furthermore, the SUN classification describes anterior chamber 
cells as in unequal steps (0, +0.5, +1, +2 and +3) estimated subjectively by the consulting 
ophthalmologist which is therefore not optimal for quantitative research. 
Skin manifestations:  
Cutaneous manifestations are common in IBD patients113 and include ectopic cutaneous IBD 
in addition to the other categories of pathologies as set out in Table 1. The diagnosis of 
cutaneous manifestations is principally based on clinical examination of the patient due to 
the inherently accessible nature of the skin. In atypical cases a skin biopsy is helpful.114 In 
skin disorders, such as psoriasis and eczema specific indexes to objectively measure skin 
disease extent and activity have been developed (e.g. the Psoriasis Area Severity Index 
  
(PASI)115-117 and the Eczema Area and Severity Index (EASI)).118 However similar standardised 
assessment techniques for cutaneous EIM of IBD such as EN and PG are lacking. The only 
randomised controlled trial of therapy for an EIM in IBD patients (infliximab for PG) 
employed a primary endpoint of clinical improvement at week 2, as determined by the 
clinician and patient’s global assessment of reduction in ulcer size and depth and the degree 
of undermining of the ulcer edge.94 Infliximab was shown to be superior to placebo, 
particularly in patients with disease duration ≤3 months. Standardisation of assessments 
methods such as that employed in this trial will enhance reproducibility in clinical research 
as well as facilitating meta-analysis of EIM research.  
In summary, current tools for the diagnosis of EIM have for the most part been developed in 
patients with unifocal inflammation. Studies to validate the use of these tools in patients 
with multifocal inflammation, including IBD patients are needed. Even better would be a 
system of diagnosis and monitoring that reflects common pathogenic mechanisms which 
could then be applied to diseases generated by that common mechanism but manifesting in 
diverse clinical phenotypes. 
Open questions: 
1. Are tools for monitoring of unifocal inflammation valid for use in patients with 
multifocal inflammation? 
2. If one of the criteria in an algorithm for diagnosing inflammatory pathology at an 
extraintestinal site is that the patient has IBD, will such an algorithm provide 
adequate diagnostic discrimination when applied to a population of IBD patients? 
3. Is a single multidimensional scale for diagnosis and monitoring of inflammation at 
multiple sites possible? Is it desirable? 
Biomarkers 
There are no specific biomarkers for EIM activity in IBD with acute phase proteins ESR and 
CRP, leucocytosis, thrombocytosis and anaemia being non-specific and in addition ESR and 
CRP having low sensitivity being elevated in only 40-50% of patients with axial SpA. 
Conversely faecal calprotectin is only validated in the diagnosis and monitoring of gut 
inflammation and does not reflect disease activity at other sites.  
  
Genetic markers for SpA:  
Genetic factors may be utilised as biomarkers in the diagnosis of inflammatory pathology119, 
120. Combining clinical factors with genetic data has been shown to be superior in predicting 
the development of EIMs compared to either alone. HLA-B27 positive IBD patients are at 
increased risk for developing AS.2 Apart from HLA-B27, over 41 genes have been identified 
predisposing to AS.121, 122 However, most of these have not been associated with increased 
risk for extra-articular inflammation. Currently there are neither reliable genetic biomarkers 
for peripheral SpA,123 119, 124 nor for cutaneous or ocular EIM. 
Imaging biomarkers for spondyloarthritis (SpA): 
Traditional X-rays are of value in diagnosing axial SpA but only demonstrate changes in 
advanced cases. MRI usually demonstrates the first radiological changes in axial SpA and is - 
despite moderate sensitivity and specificity125 - the imaging test of choice for detection of 
early disease126-128 as well as the best objective technique to assess inflammatory disease 
activity.129-134 This assessment has been standardised with the use of the Bath Ankylosing 
Spondylitis Radiology Index (BASRI).135 In peripheral arthritis which is generally non-erosive, 
joint radiography is usually normal so ultrasonography is often employed to confirm the 
diagnosis. In addition, there is no evidence to confirm or refute the assumption that 
radiological findings in inflammatory arthropathy differ between patients with patients with 
only arthritis and those with inflammation also at distal sites. 
Antimicrobial antibodies: 
IBD is associated with the presence of antibodies to a variety of microorganisms such as anti-
Saccharomyces cerevesiae antibodies (ASCA), antineutrophil cytoplasmic antibodies (ANCA), 
anti-I2 (associated with anti-Pseudomonas activity), anti-Escherichia coli outer membrane 
porin C (anti-OmpC) and anti-flagellin antibodies (anti-CBir1). Subclinical intestinal 
inflammation has been reported to be present in a significant proportion of patients with 
radiographic axial SpA.136, 137 The data on the presence of these antimicrobial antibodies in 
patients with both IBD and SpA are inconsistent and mostly relate to axial SpA. Anti-I2 
antibodies have been associated with the combination of AS and intestinal inflammation137 
as have antibodies against ASCA, anti-OmpC and anti-CBir1.138  
 
Open questions: 
  
1. Should patients with presenting with inflammatory pathologies be screened for 
multifocal inflammation? 
2. Which biomarkers would be most appropriate for screening and in which 
populations? 
3. Would biomarkers be useful to guide therapeutic decisions even in patients with 
unifocal inflammation (to reveal underlying mechanisms)? 
 
Predictors and treatment of EIM 
Predictors of EIM 
The identification of patients at risk of EIM is desirable as this raises the possibility not only 
of treatment initiation prior to permanent tissue destruction, but even the potential for 
disease prevention. Moreover, patients in whom a propensity to develop inflammatory 
disease has already declared itself in one system may provide a unique opportunity for 
targeted screening in order to detect inflammation at distant anatomical sites. Several 
studies have investigated factors influencing the risk of developing EIM but with inconsistent 
results. This is likely caused by differences across studies regarding definitions and 
assessment of EIM as well as patient populations since only very few population-based 
studies exist. Furthermore, the occurrence and risk factors for EIM may also vary 
geographically.139-141 
On the simplest level, demographic and clinical factors may be used to detect risk. For 
example, female sex,29, 63, 113, 142-146 CD rather than UC,113, 142, 143, 147, 148 increasing age,29, 143, 
149 long disease duration,142, 143 colonic location in CD,100, 143 extensive UC compared to 
proctitis,142, 147 indicators of severe disease including need for steroids,146 azathioprine,146 
biological therapy29 or surgery,100, 144, 148 and smoking both in CD29, 148 and UC29, 150 have all 
been associated with an increased risk for EIM. However, these associations are not 
reported consistently and are not replicated in all population-based studies147-149 and as 
such, this approach may have limited applicability in clinical practice. Genetic factors play an 
important role in determining the presence of EIM,119, 120 especially genes in the HLA region 
on chromosome 6 as described above.151-153 Combining clinical factors with genetic data has 
been shown to be superior to predict the development of EIM compared to either alone.119, 
  
124 Furthermore, specific features of the clinical presentation may alert the clinician to the 
potential for future EIM. For example, IBD is in the differential of any patient with ocular 
inflammation, especially in the “typical” constellation of bilateral anterior/intermediate 
granulomatous uveitis. Conversely, it is wise to monitor liver function tests especially in the 
IBD patient presenting with the clinical picture of mild, extensive colitis with rectal sparing 
and backwash ileitis, often associated with PSC. 
Screening for IBD in patients with AS has been studied with some success, although the low 
rate of development of IBD in this group made the usefulness of screening somewhat 
questionable.154 EIM are often tested for based on clinical suspicion however, screening for 
secondary diagnoses in patients with inflammatory pathologies has not yet proved a fruitful 
strategy.  
 
Open questions: 
1. Can accurate predictors of EIM be developed? 
2. Once predictors are available: Can early intervention alter the future 
development of EIM?   
 
Treatment 
A recent systematic review by Peyrin-Biroulet et al. based on nine interventional studies, 
seven open label studies and thirteen non-interventional studies found a good clinical 
efficacy of adalimumab and infliximab for the treatment of musculoskeletal, cutaneous, and 
ocular manifestations, and some beneficial effect in metabolic bone disease and 
haematological or vascular EIM in IBD patients.155 In contrast, no or limited efficacy of other 
biologic drugs including certolizumab pegol, golimumab, vedolizumab or natalizumab was 
identified. In this review however different ranges of pathology get grouped together, which 
may obscure the therapeutic effect for specific types of EIM that share a common 
mechanism. 
Paradoxical, drug-induced EIM are well documented and hint at the complex effects that 
interference with immune function may have. This complexity is potentially compounded in 
patients with multifocal inflammation. The effect of vedolizumab, (which blocks α4β7 
dependent migration of lymphocytes into the gut), on EIM has been difficult to predict, as 
  
discussed above. Potentially vedolizumab may have no effect on extraintestinal 
inflammation due to its gut-selective nature; alternatively if lymphocytes causing 
extraintestinal inflammation require activation in the gut before migration to the distant 
site, then vedolizumab would be predicted to improve EIM. Lastly, if prevention of migration 
to the gut resulted in accumulation of lymphocytes at extraintestinal sites, then vedolizumab 
could cause exacerbation of EIM. Of course, it may be that each of these mechanisms is 
present in different patients. Another treatment strategy that may be examined in the 
future is combination therapy with biologics with different molecular targets, for example, 
combined anti-integrin/anti-TNFα therapy for IBD patients with EIM has shown some 
efficacy.156  
It has been hypothesized that the extent of inflammation (for example the size of ulcerations 
in PG) may determine optimal drug dosing, with larger ulcers requiring higher doses of the 
drug.94 However no dose-response studies and no RCTs have been presented in IBD-EIM 
patients during the induction phase of anti-TNFα treatment to determine optimal trough 
levels.157 The concept of relating drug dose to total inflammatory burden has instinctive 
validity and could be potentially of great relevance to patients with EIM. However, this 
concept remains speculative at present and requires validation in clinical trials.158    
Open questions: 
1. Is there a dose-response relationship between anti-TNF therapy and EIM 
treatment response? 
2. Are all anti-TNFα antibodies equally effective for the treatment of EIM? 
3. Is there an additive effect of combined immunosuppression in IBD patients with 
EIM? 
4. Are optimal anti-TNFα trough levels for IBD patients with EIM different from 
those for IBD patients without EIM?  
 
Treat to Target and Patient Reported Outcome Measures in EIM 
A “treat to target” strategy has been developed in many areas of medicine, where treatment 
outcomes are defined by specific objective endpoints. The concept driving this strategy is 
that traditional outcome measures fail to reflect subclinical, yet active disease, permitting 
the accumulation of tissue damage over time. With a treat-to-target strategy therapy is 
  
intensified until the relevant evidence-based treatment target is in the desired range, which 
is associated with a reduction in end-organ destruction. For example in rheumatoid arthritis 
and scores such as the Disease Activity Score Calculator for Rheumatoid Arthritis (DAS-28) 
have been established.159 This approach has also been used successfully in endocrinology 
especially in diabetes management.160-162 Ongoing studies are developing this strategy in 
IBD.163 Whether the same treatment targets developed for unifocal inflammation, can be 
applied (individually or perhaps in combination) in IBD-EIM or whether different targets 
should be developed, is unclear. 
Another current advancement in the care of patients with chronic conditions is the 
development of Patient Reported Outcome Measures (PROM), which may themselves 
function as a treatment target.  PROM are defined by the FDA as “any report of the status of 
a patient’s health condition that comes directly from the patient, without interpretation of 
the patient’s response by a clinician or anyone else.”164 PROM may be disease specific such 
as the Inflammatory Bowel Disease Questionnaire (IBDQ-32),165 the Inflammatory Bowel 
Disease Quality of Life Questionnaire (IBDQOL)166 or the Work Productivity and Activity 
Impairment: Crohn’s Disease (WPAI: CD).167 The use of PROM designed for the assessment of 
unifocal inflammation in patients with multifocal inflammation presents obvious drawbacks, 
potentially missing significant aspects of the patient’s experience. However, non-disease 
specific instruments have been developed such as the Short Form Health Survey168 and the 
EQ-5D,169 which may be more applicable in multifocal inflammation. 
Open questions: 
1. What are appropriate treatment targets for patients with multifocal inflammation? 
2. Can established treatment targets from patients with joint, skin or eye disease be 
employed for patients with EIM in IBD? 
3. Would there be a difference in how PROM and treat to target strategies function in 
patients with EIM activity that is synchronous with the IBD activity compared with 
patients with asynchronous disease activity? 
CONCLUSION 
Determining the mechanisms that cause inflammation to manifest unifocally or multifocally 
in different patients remains an enticing conundrum in immunology. Solving this conundrum 
may illuminate novel mechanisms and reveal a broader range of therapeutic targets. In the 
  
context of the availability of a greater number of drugs targeted toward this broadening 
range of molecular targets, the previous organ-based approach to inflammatory disease may 
be inadequate. A holistic approach to the diagnosis and monitoring of inflammatory disease 
will allow a personalised therapeutic strategy. New tools for monitoring multifocal 
inflammation are needed in order to better capture the experience of the patient. This 
holistic approach to inflammatory disease requires greater cooperation between specialities 
and across research disciplines. 
  
  
Figures 
Figure 1. See separate document 
  
  
Figure legend  
Figure 1 Potential mechanisms of EIM 
I Extension of immune responses from the intestine 
A. Ectopic expression of adhesion molecules and chemokines e.g. ectopic expression of 
MAdCAM-1 and CCL25 in the vascular endothelium of the portal tract 
B. T cell trafficking driven by non-specific adhesion molecules e.g. α4β7-independent 
binding of leukocytes to the synovial membrane using a repertoire of adhesion 
molecules. Non-specific interactions may be initiated after low-grade inflammation, 
injury or mechanical stress 
C. Microbial antigen translocation e.g. via portal tracts 
D. Microbial antigen cross reactivity e.g. molecular mimicry between enteric bacteria and 
host MHC molecules 
E. Circulating antibodies that may bind epitopes shared between human colon and 
extraintestinal tissues 
 
II EIM as independent inflammatory events 
F. Shift in inflammatory tone driven by genetic, environmental or microbial factors or by 
systemic increase in key inflammatory mediators 
G. Systemic changes in innate immune function e.g. neutrophil priming 
H. Altered haematopoiesis driven by microbial products, intestinal inflammation, 
systemic inflammatory cytokines, increased gut permeability, changes in the 
composition or metabolic products of the microbiota 
I. Gut microbiota drives distant inflammation via microbial products such as LPS, 
through changes in gut permeability, microbiota-derived metabolites   
  
Tables 
Table 1. Suggested categorisation of extraintestinal conditions that occur in IBD patients, (list 
of extraintestinal conditions associated with IBD adapted from Harbord et al.2). 
 
System A. 
Extraintestinal 
manifestations 
(multifocal 
inflammation) 
B. 
Complications of IBD 
and its treatment 
C. 
Associated conditions 
with uncertain 
mechanism 
Joints and 
bones 
 
Spondyloarthritis Metabolic bone 
disease/ osteoporosis - 
(drug or nutritionally 
induced) 
Non-inflammatory 
arthralgia 
Eye Uveitis 
Episcleritis 
Scleritis 
Drug induced cataracts 
and other drug-induced 
and nutritional eye 
disease (see 
supplementary figure 
4) 
 
Oral, aural 
and nasal  
Oral CD 
Orofacial 
granulomatosis 
Metastatic CD 
 Sensorineural hearing 
loss 
Skin Erythema nodosum 
Pyoderma 
gangrenosum 
Sweet syndrome 
Metastatic CD 
Drug-induced skin 
disease (e.g. anti-TNF 
induced psoriasis, DILE) 
Drug-induced skin 
cancer 
Drug hypersensitivity 
Vitiligo 
Psoriasis 
Eczema 
Epidermolysis bullosa 
acquisita 
Cutaneous polyarteritis 
nodosa 
Hidradenitis 
  
suppurativa 
Urogenital Metastatic CD Nephrolithiasis 
Amyloidosis 
Drug-induced tubulo-
interstitial nephritis 
 
 
Hepato-
pancreato-
biliary  
PSC Portal vein thrombosis 
Hepatic amyloidosis 
DILI 
Drug-induced 
pancreatitis 
Autoimmune hepatitis 
Granulomatous 
hepatitis 
Autoimmune 
pancreatitis 
Neurological  Peripheral neuropathy 
(drug or nutritionally 
induced) 
Venous sinus 
thrombosis 
Stroke 
Central demyelination 
Cardiovascular  Ischaemic heart disease 
Cerebrovascular 
accident 
Mesenteric ischaemia 
 
Pulmonary  Drug-induced lung 
fibrosis 
Inflammatory bronchial 
and parenchymal lung 
disease including 
asthma, bronchiectasis 
and  interstitial 
pneumonias 
Coagulopathy  Venous 
thromboembolism 
 
Endocrine  Drug-induced Cushing’s 
and Addison syndromes 
Drug-induced diabetes 
Type 1 diabetes  
Autoimmune thyroid 
disease 
  
Infection  Infections including 
systemic and local 
secondary to 
immunosuppression 
Septic complications of 
IBD or surgery 
 
IBD: Inflammatory bowel disease, CD: Crohn’s disease, DILE: Drug-induced lupus 
erythematosus, PSC: primary sclerosing cholangitis, DILI: Drug-induced liver injury 
 
A. For several conditions there is evidence for a mechanistic link between two pathologies, 
as described by the definition put forward in this paper of a “true” extraintestinal 
manifestation (EIM) of IBD. We would propose that these conditions may also be considered 
multifocal inflammation. 
B. Other conditions that occur in IBD patients are complications of the disease or its surgical 
or pharmacological management. 
C. Several conditions occur more commonly in IBD patients but there is lack of evidence to 
categorise these as either complications or directly link them mechanistically to IBD. It is 
likely that as pathogenic mechanisms are better understood it may be possible to re-classify 
some of these conditions as “true” EIM/ multifocal inflammation. 
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